Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2013-05-29

FDA Approved: OXYTROL — Supplemental Application (Allergan, Inc.)

View source ↗

Summary

FDA approved a supplemental application for OXYTROL (oxybutynin), the transdermal patch from Allergan, Inc., signifying approval of updated labeling and/or indi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • OXYTROL (OXYBUTYNIN)

Snippet

SUPPL AP for OXYTROL (OXYBUTYNIN)